DrugPatentWatch Database Preview

Details for Patent: 7,320,802

« Back to Dashboard

Which drugs does patent 7,320,802 protect, and when does it expire?

Patent 7,320,802 protects TRICOR and is included in one NDA.

This patent has one hundred and fifty-four patent family members in twenty-seven countries.

Summary for Patent: 7,320,802

Title:	Methods of treatment using nanoparticulate fenofibrate compositions
Abstract:	The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
Inventor(s):	Ryde; Tuula (Malvern, PA), Gustow; Evan E. (Villanova, PA), Ruddy; Stephen B. (Schwenksville, PA), Jain; Rajeev (Collegeville, PA), Patel; Rakesh (Bensalem, PA), Wilkins; Michael John (Midleton, IE)
Assignee:	Elan Pharma International, Ltd. (Athlone, County Westmath, IL) Fournier Laboratories Ireland Ltd. (Cork, IL)
Application Number:	10/692,855
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,320,802

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-001	Nov 5, 2004	AB	RX	Yes	No						ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-002	Nov 5, 2004	AB	RX	Yes	Yes						ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

Non-Orange Book US Patents Family Members for Patent 7,320,802

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,652,464	Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer
7,276,249	Nanoparticulate fibrate formulations
7,198,795	In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
6,428,814	Bioadhesive nanoparticulate compositions having cationic surface stabilizers

International Patents Family Members for US Patent 7,320,802

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	040110
Argentina	072134
Argentina	072135
Austria	293959